Cargando…

PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis

The peroxisome proliferator activated receptor (PPAR)γ agonist is used as antidiabetic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these actions, antifibrotic effects have been reported. We examined antifibrotic effects of PPARγ agonist and interaction with angiotensin rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Jee-Young, Kim, Ye-Ji, Kim, Lucia, Choi, Suk-Jin, Park, In-Suh, Kim, Joon-Mee, Chu, Young Chae, Cha, Dae-Ryong
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799997/ https://www.ncbi.nlm.nih.gov/pubmed/20052345 http://dx.doi.org/10.3346/jkms.2010.25.1.35

Ejemplares similares

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice
por: Min, Hye Sook, et al.
Publicado: (2021)

Potent Anti-Diabetic Effects of MHY908, a Newly Synthesized PPAR α/γ Dual Agonist in db/db Mice
por: Park, Min Hi, et al.
Publicado: (2013)

The Novel PPAR α/γ Dual Agonist MHY 966 Modulates UVB–Induced Skin Inflammation by Inhibiting NF-κB Activity
por: Park, Min Hi, et al.
Publicado: (2013)

PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix
por: Frkic, Rebecca L., et al.
Publicado: (2018)

Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist
por: Goto, Tsuyoshi, et al.
Publicado: (2011)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts
por: Koo, Jun Bon, et al.
Publicado: (2017)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Effects of a PPAR -gamma receptor agonist and an angiotensin receptor antagonist on aortic contractile responses to alpha receptor agonists in diabetic and/or hypertensive rats
por: Tugrul, Ibrahim, et al.
Publicado: (2016)

Cyclooxygenase-2 Inhibitor Parecoxib Was Disclosed as a PPAR-γ Agonist by In Silico and In Vitro Assay
por: Xiao, Bin, et al.
Publicado: (2021)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ
por: Kim, Dong Hyun, et al.
Publicado: (2020)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-γ Agonist
por: Su, Mingzhi, et al.
Publicado: (2017)

Identification of Bexarotene as a PPARγ Antagonist with HDX
por: Marciano, David P., et al.
Publicado: (2015)

GW501516, a PPARδ Agonist, Ameliorates Tubulointerstitial Inflammation in Proteinuric Kidney Disease via Inhibition of TAK1-NFκB Pathway in Mice
por: Yang, Xu, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency
por: Zhang, Yu, et al.
Publicado: (2016)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

PPAR-γ Agonist GW1929 But Not Antagonist GW9662 Reduces TBBPA-Induced Neurotoxicity in Primary Neocortical Cells
por: Wojtowicz, Anna K., et al.
Publicado: (2013)

An Algal Metabolite-Based PPAR-γ Agonist Displayed Anti-Inflammatory Effect via Inhibition of the NF-κB Pathway
por: Ju, Zhiran, et al.
Publicado: (2019)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

PPARγ sumoylation-mediated lipid accumulation in lung cancer
por: Phan, Ai N.H., et al.
Publicado: (2017)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy
por: Hou, Xiaoyan, et al.
Publicado: (2016)

CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARγ pathway
por: Bai, Xiaoyan, et al.
Publicado: (2016)

Identification of an irreversible PPARγ antagonist with potent anticancer activity
por: Peng, Youyi, et al.
Publicado: (2020)

Synthesis of Phthalimide Derivatives as Potential PPAR-γ Ligands
por: Eom, So Hyeon, et al.
Publicado: (2016)

Identification of a Novel PPAR-γ Agonist through a Scaffold Tuning Approach
por: Gim, Hyo Jin, et al.
Publicado: (2018)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ffkfpf37q9sgqmev65vdbekleo